title: [A case of male breast cancer in which oncotype DX was used to determine the therapeutic strategy].
abstract: Male breast cancer is rare, and reportedly to accounts for less than 1% of all breast cancers. Postoperative therapy of male breast cancer is similar to that for female cancer. We experienced a male patient and used oncotype DX to determine the therapeutic strategy. A 60-year-old man was diagnosed with breast cancer Stage I. He underwent sentinel lymph node biopsy and mastectomy, but lymph node dissection was omitted. However, micro-metastases were found in the permanent specimen. Later, axillary node dissection was performed. The patient was finally diagnosed with Stage IIA (T1c, N1mi, M0) and luminal A type breast cancer. From using oncotype DX to determine the therapeutic strategy, the recurrence score was 8 and within the low recurrence score group. Currently, we are only administering endocrine therapy.
authors.affiliation: Dept. of Gastroenterology and General Surgery, Nara Medical University, Japan.
authors.forename: Junko
authors.initials: J
authors.lastname: Yokoyama
authors.forename: Toyoki
authors.initials: T
authors.lastname: Kobayashi
authors.forename: Takashi
authors.initials: T
authors.lastname: Nakamura
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Nakajima
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D018567:Breast Neoplasms, Male / Q000473:pathology / Q000628:therapy*; D044584:Carcinoma, Ductal / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D021701:Sentinel Lymph Node Biopsy; D013629:Tamoxifen / Q000627:therapeutic use
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen